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Macrophages are exploited from an innate wound
healing response to facilitate cancer metastasis
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Tumour-associated macrophages (TAMs) play an important role in tumour progression,
which is facilitated by their ability to respond to environmental cues. Here we report, using
murine models of breast cancer, that TAMs expressing ﬁbroblast activation protein alpha
(FAP) and haem oxygenase-1 (HO-1), which are also found in human breast cancer, represent
a macrophage phenotype similar to that observed during the wound healing response.
Importantly, the expression of a wound-like cytokine response within the tumour is clinically
associated with poor prognosis in a variety of cancers. We show that co-expression of FAP
and HO-1 in macrophages results from an innate early regenerative response driven by IL-6,
which both directly regulates HO-1 expression and licenses FAP expression in a skin-like
collagen-rich environment. We show that tumours can exploit this response to facilitate
transendothelial migration and metastatic spread of the disease, which can be pharmaco-
logically targeted using a clinically relevant HO-1 inhibitor.
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Tumour-associated macrophages (TAMs) form part of thestromal cell inﬁltrate in solid tumours1, and promotetumour progression through supporting angiogenesis2,
immune suppression3, chemotherapeutic resistance4–6 and
tumour cell migration7,8. However, within the TAM population it
has been demonstrated that there are phenotypic subsets with
speciﬁc specialised roles3,9,10. A subpopulation of F4/80hi TAMs
was identiﬁed in subcutaneous murine Lewis lung adenocarci-
noma (LL2) tumours, which expressed surface ﬁbroblast activa-
tion protein alpha (FAP) and intracellular haem oxygenase-1
(HO-1) and accounted for 10% of total F4/80hi cells3. FAP is a
dipeptidyl peptidase capable of degrading gelatin and type I
collagen11,12, and also has a role in cellular signalling in cancer-
associated ﬁbroblasts (CAFs)13. HO-1 is an inducible enzyme
responsible for the breakdown of haem to generate biliverdin,
ferrous iron and carbon monoxide (CO)14. Selective conditional
ablation of the FAP+ TAM population in an immunogenic
ovalbumin (OVA)-expressing LL2 tumour using diphtheria toxin
in bone marrow chimeric FAP/diphtheria toxin receptor trans-
genic (DTR Tg) mice, resulted in an immunological control of
tumour growth demonstrating that this macrophage subset
played an important role in immune suppression3,15. FAP+
TAMs represented the major tumoural source of HO-1 and
pharmacological inhibition of this enzyme paralleled the obser-
vations made with conditional depletion of the producing cells,
suggesting that HO-1 was essential to their biological function
within the tumour3. As FAP+ TAMs can also be found in human
breast tumours16, it is important to elucidate the full biological
implications of this TAM subset, as well as their origin.
Macrophages are one of the most plastic cells of the immune
system and display an exquisite ability to respond to environ-
mental cues which shape their phenotype17. The biological
responses of these cells are exploited by the tumour to drive
progression of the disease. In the current study, we highlight the
ability of the tumour to orchestrate a microenvironment which
phenocopies the cytokine milieu and extracellular matrix of a
superﬁcial wound. As a result, the macrophages are coerced to
instigate a wound healing response, identiﬁed by co-expression of
FAP and HO-1, exemplifying Harold Dvorak’s seminal observa-
tion 40 years ago that cancers resemble ‘wounds that do not
heal’18. This study demonstrates that tumours exploit the innate
regenerative response of macrophages to facilitate metastatic
spread of the disease.
Results
FAP+ HO-1+ TAMs represent a tumour-educated phenotype.
Selective conditional ablation of FAP+ HO-1+ TAMs, or phar-
macological inhibition of their HO-1 activity, results in a cessa-
tion of tumour growth in subcutaneously implanted
immunogenic LL2/OVA tumours, suggesting that these cells are a
non-redundant population within the tumour microenvironment,
and that HO-1 expression might represent a key effector molecule
in their pro-tumorigenic functions3. As FAP+ TAMs have been
demonstrated to reside in human mammary adenocarcinoma16,
we investigated whether these cells within the human
tumour microenvironment could also express HO-1. Indeed,
FAP+ HO-1+ CD11b+ myeloid cells could be found in tissue
sections of human mammary adenocarcinoma (Fig. 1a, b), indi-
cating that this phenotype is conserved across murine and human
tumours. These FAP+ HO-1+ cells co-expressed the myeloid
marker CD14 (Supplementary Figure 1a), suggesting that they are
TAMs. To gain biological insight into the origin of these cells in
breast cancer, we utilised an orthotopic model of mammary
adenocarcinoma in which 4T1 tumour cells are injected into the
mammary fat pad of Balb/c syngeneic mice19. The F4/80+ TAMs
present in these tumours represented 10.8 ± 3.3% of all live
tumoural cells (Fig. 1c) and expressed FAP, alongside the mac-
rophage/TAM markers CCR2, CD11b, CD14, MHCII, IL4-R and
MMR, with a low expression of the dendritic cell marker CD11c
(Fig. 1d and Supplementary Figure 1b). CD11b+ Ly6Chi mono-
cytes, which had yet to differentiate to TAMs, did not express
FAP (Fig. 1e), suggesting that FAP represented a differentiation
marker. The expression of FAP by the macrophages was a stable
phenotype in this model, and was constant during the growth of
4T1 tumours (Fig. 1f and Supplementary Figure 1c). Expression
of tumoural Hmox1, the gene encoding HO-1, was also detected
at the point of tumour establishment (day 9 post inoculation)
(Fig. 1g and Supplementary Figure 1c) and was associated with
the TAM population, where its expression correlated with FAP
(Fig. 1h). The FAP+ TAM phenotype was not a biological
response to the microenvironment of the mammary fat pad in
which the tumour cells were injected as TAMs in another
orthotopic murine model of mammary adenocarcinoma,
E077120,21, grown at the same anatomical location in syngeneic
C57Bl/6 mice, did not express FAP (Fig. 1i) and expressed lower
levels of Hmox1 (Fig. 1j). Tumours have been demonstrated to
expand populations of myeloid cells, which are functionally dis-
tinct from inﬂammatory monocytes22–24. 4T1 tumour cells, when
injected into mice, expand peripheral populations of myeloid cells
primarily through the secretion of granulocyte colony-stimulating
factor (G-CSF)25 (Supplementary Figure 1d), a phenomenon
which has also been observed in the clinic26. To exclude the
possibility that the FAP+ TAM population represents a pre-
deﬁned differentiation state, G-CSF was ectopically expressed in
E0771 cells and these cells were injected into C57Bl/6 syngeneic
mice, resulting in an expansion of peripheral myeloid cell
populations (Supplementary Figure 1e, f). However, this did not
result in the presence of FAP+ macrophages in these tumours
(Supplementary Figure 1g), indicating that FAP+ TAMs are not
directly derived from this G-CSF-induced myeloid population. To
exclude any effect of strain differences in the TAM response27,
4T1 and E0771 cells were concurrently injected into opposing
mammary fat pads of Balb/c Rag2−/−-immunocompromised
mice (syngeneic to the 4T1 cells in which FAP+ HO-1+ TAMs
had been identiﬁed). At day 21 post inoculation, both tumours
were excised (Supplementary Figure 1h) and their respective
TAM phenotypes assessed. In this setting, FAP+ TAMs, which
highly expressed Hmox1, were exclusively populating the 4T1 and
not the E0771 tumours (Fig. 1k, l). These data collectively
prompted the conclusion that FAP+ HO-1+ TAMs represent a
tumour-educated phenotype rather than an autonomous per-
ipherally derived population.
FAP+ HO-1+ macrophages are associated with a wound
response. Having established that the FAP+ macrophage phe-
notype was a response to the microenvironment, we considered
whether any population of tissue-resident macrophages might
express FAP during homoeostasis. Therefore, CD45+ F4/80+
macrophages from healthy tissues were analysed for FAP
expression. FAP expression could not be detected on CD45+ F4/
80+ tissue macrophages populating the liver, brain, lung, kidney,
heart, spleen or visceral adipose (Supplementary Figure 2a). This
suggested that the FAP+ phenotype might have represented a
speciﬁc response programme of these cells. To gain further bio-
logical insight into the FAP+ HO-1+ macrophage phenotype,
TAMs were sorted from 4T1 tumours and analysed by micro-
array for changes in gene expression relative to basal M-CSF-
differentiated splenic-derived macrophages (Fig. 2a). Gene
ontology enrichment analysis of the transcriptome of these cells
revealed a collection of immune-response pathways, including
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pathways relating to the wound healing response (Fig. 2b). As
tumours and healing wounds share many similarities18, it
prompted the consideration that the expression of FAP and HO-1
by macrophages might represent part of a wound healing
response programme of these cells. We therefore analysed the
abundance of FAP+ HO-1+ macrophages in healthy and woun-
ded skin of mice 2 days (acute injury inﬂammatory response
phase) and 6 days (wound healing response phase) after full-
thickness dorsal skin wounding by a punch biopsy28–31 (Fig. 2c, d
and Supplementary Figure 2b). Indeed, FAP+ HO-1+ macro-
phages could be found in the granulation tissue at both 2 and
6 days post wounding (pw, Fig. 2d, e and Supplementary Fig-
ure 2b). FAP+ HO-1+ macrophages accounted for 14 ± 8% of F4/
80+ cells at day 2 pw and were maintained at an equal prevalence
at day 6 pw (Fig. 2f, g). As expected, F4/80+ macrophages
accumulated at the wound edge between days 2 and 6 pw32
(Fig. 2f); however, there was no increased prevalence of FAP+
HO-1+ macrophages at this site (Fig. 2g), suggesting that FAP+
HO-1+ macrophages were a phenotype associated with the
granulation tissue.
These observations suggest that the FAP+ HO-1+ macro-
phages in tumours share similarities to those of an innate wound
healing response, potentially being exploited by the tumour.
4T1 tumours phenocopy a wound cytokine response. As we
established that the FAP+ HO-1+ macrophage phenotype can be
detected during the reparative inﬂammation phase of the wound
response of the dorsal skin, we assessed the transcriptome of a
murine wound at the same site28 for potential secreted molecules
which might direct macrophage differentiation and polarisation.
In the acute inﬂammatory phase of the wound healing response,
Spp1, Il1b, Csf3, Il6, Osm and Il24 were signiﬁcantly upregulated
(fold change >16; ANOVA, P < 0.05) relative to unwounded skin
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(Fig. 2h), with the peak of the cytokine response occurring at 24 h
pw (Fig. 2i). The relative peak of the inﬂammatory response to
wounding coincided with the identiﬁcation of FAP+ HO-1+
macrophages in the granulation tissue by confocal microscopy
analysis at day 2 pw (Fig. 2g). The expression levels of these
cytokines were assessed in 4T1 tumours, which revealed a striking
similarity to the reparative tissue response, including signiﬁcantly
higher Spp1, Il1b, Csf3, Il6 and Osm expression in 4T1 tumours
compared to healthy mammary fat pad tissue (Fig. 2j). This
wound-like cytokine mileu was not detected in E0771 tumours
which were devoid of FAP+ TAMs (Fig. 2j), demonstrating that
this cytokine environment was speciﬁc to the 4T1 model and
associated with the presence of FAP+ TAMs. Expression of Il4,
Il10 and Il13, which represent cytokines commonly associated
with alternative macrophage activation, was undetectable in 4T1
tumours (Fig. 2j). No difference in expression levels of Il24 was
observed between 4T1 and E0771 tumours (Fig. 2j), which was
expected since IL-24 is a known tumour suppressor gene33,
inhibiting cell proliferation and migration in the wound healing
context and thus preventing tumorigenesis34. Analysis of the
microarray data for the FAP+ TAM population isolated from 4T1
tumours (Fig. 2a) revealed that these cells were also directly
expressing some of the acute wound inﬂammatory response
genes, including Il1b, Il6 and Osm, alongside the phenotypic
markers Hmox1 and Fap (Fig. 2k). Interestingly, these TAMs, as a
collective population, also displayed characteristics of both
alternative (Arg1, Ym1, Il10 and Fizz1) and classical (Nos2 and
Tnf) macrophage activation (Fig. 2k), consistent with that pre-
viously described for both TAMs and wound healing
macrophages35.
Healing wound cytokines indicate poor prognosis in cancer. To
investigate whether the inﬂammatory cytokine response observed
in the murine models was conserved among species we investi-
gated a human wound transcriptome data set. Several of the genes
observed to be upregulated in the murine models, including IL1B,
IL6 and SPP1, were also highly over-expressed after thermal
injury of human skin36 (Supplementary Figure 3a) and in
superﬁcial wounds resulting from human skin grafting37 (Sup-
plementary Figure 3b). We therefore deﬁned the species-
conserved healing wound cytokines (HWCs) as SPP1, IL1B and
IL6, and considered whether the expression levels of these genes
might have prognostic value in human cancers. Interestingly, high
expression of HWCs in breast cancer was associated with poor
prognosis (Fig. 3a). This association was not speciﬁc for breast
cancer, but also observed in lung, gastric and ovarian cancer
(Fig. 3b–d). These observations indicate that tumours can create a
cytokine microenvironment associated with tumour progression,
which is similar to that of an acute inﬂammatory wound healing
response.
IL-6 regulates HO-1 expression in macrophages. To investigate
the effect of the murine inﬂammatory wound response cytokines
on the macrophage phenotype, bone marrow (BM) cells were
incubated for 72 h with M-CSF to induce macrophage differ-
entiation in the presence or absence of the respective cytokines,
and then subsequently analysed for Hmox1 gene expression. As a
comparator, macrophages were also stimulated with IL-4, a
cytokine commonly associated with the TAM phenotype7,38. IL-6
stimulation evoked a striking upregulation of Hmox1 expression
(Fig. 4a). However, IL-6 alone did not account for the wider
prognostic value of the HWCs in the Kaplan–Meier plotter data
set (Supplementary Figure 3c), but, IL-6 has been demonstrated
to be associated with poor overall and disease-speciﬁc survival
(DSS) by others39. The ability of IL-6 to regulate HO-1 was not
speciﬁc to BM-derived macrophages (BMDM), as IL-6 also
upregulated HO-1 in splenic Ly6Chi monocyte-derived macro-
phages (Fig. 4b and Supplementary Figure 4a). In contrast,
alternative (IL-4) and classical (IFNγ/LPS) macrophage activation
programmes resulted in less HO-1 expression than IL-6 stimu-
lation (Fig. 4b and Supplementary Figure 4a). The IL-6-HO-1 axis
was also not species speciﬁc as IL-6 signiﬁcantly upregulated HO-
1 in human CD14+ monocyte-derived macrophages (Fig. 4b, c
and Supplementary Figure 4b). 4T1 tumours express high levels
of Il6 mRNA (Fig. 2j), and the protein could be detected in the
serum (Fig. 4d). As such, we investigated the tumoural source of
IL-6 in sorted populations of cells from 4T1 tumours and iden-
tiﬁed that Il6 expression was restricted to the stroma in this
model, with the TAMs expressing the highest levels (Fig. 4e).
Collectively, these data suggest that HO-1 expression by macro-
phages is a characteristic of the IL-6 polarisation programme.
Collagen licences IL-6-dependent FAP expression. We investi-
gated whether IL-6 could also regulate FAP expression in BMDM;
however, IL-6 alone was insufﬁcient to induce FAP expression on
these cells (Fig. 4f). This suggested that a secondary signal might
be required. FAP is capable of degrading type I collagen11, which
is a major extracellular matrix (ECM) protein of the dermal layer
Fig. 1 FAP+ HO-1+ TAMs in human and mouse breast adenocarcinoma are a tumour-educated phenotype. a, b Representative images of frozen human
invasive ductal mammary carcinoma sections stained with DAPI (nuclei; blue) and antibodies against CD11b (green), FAP (yellow) and HO-1 (red)
(representative images from n= 3 tumours). Arrows indicate cells co-expressing CD11b, FAP and HO-1. c, d Abundance (c) and surface characterisation
(d) of live (7AAD−) CD45+ F4/80+ TAMs from enzyme-dispersed 4T1 tumours (at day 24 post inoculation) as assessed using ﬂow cytometry. Each
point in c represents live F4/80+ cells in an individual tumour. Histograms represent positive staining for the markers shown (blue shaded) against that of
the respective isotype controls (grey shaded). e Flow cytometry gating strategy for live CD11b+ F4/80low Ly6Chi monocytes in a representative enzyme-
dispersed 4T1 tumour; histogram shows surface FAP staining (red shaded) against that of the isotype control (grey shaded). f Median ﬂuorescence
intensity (MFI) of FAP surface expression with ﬂuorescence minus one (FMO) background staining subtracted on CD45+ F4/80+ TAMs from enzyme-
dispersed 4T1 tumours on the indicated day post injection of the tumour cells (n= 6). g, h Hmox1 mRNA expression relative to the housekeeping gene Tbp
in 4T1 tumour tissue on the indicated day post inoculation of the tumour cells (n= 6–8 tumours per time point) (g) and FACS-sorted monocytes, FAPlo
F4/80hi TAMs and FAPhi F4/80hi TAMs and 4T1 tumour cells (CD45− Thy1.2− CD31−) from duplicate wells from a 4T1 tumour, data representative of
duplicate experiments (h). i Representative FAP staining of live (7AAD−) CD45+ F4/80hi TAMs from an enzyme-dispersed E0771 tumour as assessed
using ﬂow cytometry. Histogram represents positive staining for FAP (black line) against isotype control staining (grey shaded). j Hmox1 mRNA expression
relative to the housekeeping gene Tbp in FACS-sorted monocytes (CD11b+ F4/80lo Ly6Chi) and TAMs (F4/80hi) from duplicate wells from an E0771
tumour, data representative of duplicate experiments. k, l 4T1 (blue) and E0771 (black open) tumours were grown concurrently in opposing mammary fat
pads in Rag2−/− mice. k Schematic representation of the experimental setting (top) and representative FAP expression as assessed using ﬂow cytometry
on live CD45+ F4/80hi TAMs from enzyme-dispersed tumours (bottom). l Hmox1 mRNA expression relative to the housekeeping gene Tbp in MACS-
sorted TAMs from enzyme-dispersed tumours (n= 4). Bar charts represent mean + s.d. *P < 0.05
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of the skin that can play an important role in shaping cutaneous
cellular responses40. We therefore considered whether FAP
expression might be a response to the collagen-rich environment.
To investigate if type I collagen could induce FAP expression in
BMDMs, macrophages differentiated in the presence or absence
of IL-6 were plated onto a 3D type I collagen matrix. This resulted
in transient IL-6-dependent induction of FAP expression (Fig. 4g
and Supplementary Figure 4c), suggesting that collagen can
provide a contextual location signal to these cells, shaping their
response to IL-6. To date, the only transcription factor known to
be critical for expression of the Fap gene is EGR141. In agreement,
alongside FAP expression, there was a concomitant induction of
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EGR1 expression in IL-6-stimulated BMDMs plated onto a col-
lagen matrix (Fig. 4g and Supplementary Figure 4c). To extra-
polate these in vitro ﬁndings back to our in vivo models, ﬁbrillar
collagen was analysed in healing wounds and tumours by second-
harmonic generation (SHG) imaging. A dense ﬁbrillar collagen
network could be detected in healing wounds which was also
present in healthy skin (Fig. 4h and Supplementary Figure 5a) as
well as in 4T1 but not E0771 tumours (Fig. 4i, j and Supple-
mentary Figure 5a). The ECM was strikingly different between
4T1 and E0771 tumours (Supplementary Figure 5b). In parti-
cular, expression of Col1a1, the gene for type 1 collagen and the
substrate for FAP, was signiﬁcantly higher in the 4T1 tumours
(Fig. 4k). There was no inter-tumour correlation of the TAM’s
expression of FAP and tumoral Col1a1 expression (Supplemen-
tary Figure 5c). However, broadly the expression of Col1a1 in 4T1
tumours was equivalent to that found in the skin (Supplementary
Figure 5d). As both IL-6 and collagen are highly abundant in
healing wounds, these ﬁndings suggest that tumours can mimic a
wound-like microenvironment which maintains an FAP+ HO-1+
TAM phenotype.
IL-6 regulates the FAP+ HO-1+ TAM phenotype in 4T1
tumours. To investigate whether IL-6 is capable of orchestrating
the FAP+ HO-1+ TAM phenotype in 4T1 tumours in vivo,
4T1 cells were injected into syngeneic Balb/c WT and Il6−/− mice
(Fig. 5a). The tumours grew equally well in the absence of IL-6,
and at day 23 tumours were excised and analysed. In 4T1
tumours grown in Il6−/− mice, there was a modest increase in the
proportion of TAMs (Fig. 5b). However, in agreement with the
in vitro observations (Fig. 4g), in the absence of IL-6, the TAMs
expressed signiﬁcantly less FAP (Fig. 5c) and fewer had detectable
HO-1 (Fig. 5d, e and Supplementary Figure 6a). These data
conﬁrm that IL-6 is important in shaping the TAMs towards an
innate wound healing macrophage phenotype. Interestingly, not
all TAMs in WT 4T1 tumours had detectable HO-1, however this
might be explained by differences in the differentiation state of
these cells, as both monocytes and TAMs express F4/80 (Fig. 1d,
e), and HO-1 expression correlated with FAP expression in the
TAM population (Fig. 1h). As FAP expression was associated
with EGR1 upregulation (Fig. 4), we assessed the presence of
nuclear EGR1 in TAMs in 4T1 tumours grown in WT and Il6−/−
mice and found a signiﬁcant reduction of nuclear EGR1 in the
TAMs of Il6−/−mice (Fig. 5f, g). Both expression (Supplementary
Figure 6b) and nuclear translocation (Supplementary Figure 6c)
of EGR1 were reduced in F4/80+ TAMs in Il6−/− tumours,
suggesting that loss of nuclear EGR1 expression might be
responsible for the reduction of FAP expression by TAMs in the
absence of IL-6. FAP is more widely associated with a population
of CAFs in the tumour microenvironment15. In the absence of IL-
6 there was a small, but signiﬁcant reduction in Thy1+ CAF
abundance (Supplementary Figure 6d, e); however, their surface
expression of FAP was unaffected (Supplementary Figure 6d, f),
suggesting that the IL-6-dependent FAP expression observed in
the TAM population was a cell-speciﬁc response. IL-6 has also
been shown to regulate collagen expression42, however, Col1a1
(Fig. 5h) as well as other ECM proteins expressed in 4T1 tumours
(Supplementary Figure 5b) Col3a1, Tnc and Fn1, were unaffected
by the loss of IL-6 (Supplementary Figure 6g–i). These data
demonstrate that IL-6 is a key regulator of the FAP+ HO-1+
macrophage wound healing response phenotype.
FAP+ HO-1+ TAMs are associated with metastasis. Having
established that the FAP+ HO-1+ TAM phenotype was regulated
by IL-6 signalling, we next considered whether these cells might
also populate speciﬁc anatomical locations within the 4T1
tumour, and discovered a tendency for these cells to accumulate
around viable vasculature (Fig. 6a, b and Supplementary Fig-
ure 7a). Since tumour cells and macrophages have been
demonstrated to be closely associated during the intravasation
event across the endothelium43,44 and epithelial cell proliferation
and migration is a crucial part of the wound healing response45,
we considered whether FAP+ HO-1+ macrophages might facil-
itate metastatic spread. We therefore treated mice bearing
established 4T1 tumours with a clinically relevant HO-1 inhibitor,
tin mesoporphyrin (SnMP)3,46,47. SnMP treatment did not affect
primary tumour growth (Fig. 6c), but signiﬁcantly suppressed
pulmonary metastasis when analysed at day 24 post inoculation
of tumour cells (Fig. 6d). The composition of the stroma in 4T1
tumours remained largely constant over time, with the most
pertinent changes being a steady increase in the fraction of
neutrophils (Supplementary Figure 7b, c), which have been
implicated in the metastatic cascade48, and a slight but steady
decrease in the fraction of TAMs and CAFs. However, inhibition
of HO activity did not affect the abundance of myeloid cells in
these tumours (Fig. 6e). Lung metastasis-associated macrophages
(MAMs)10 and neutrophils48 have been demonstrated to play key
roles in the establishment of pulmonary metastasis. However,
MAMs were distinct from the TAMs as they did not express FAP
(Fig. 6f, g), and SnMP treatment did not affect MAM or neu-
trophil numbers in the lung (Fig. 6h, i). In order to elucidate
whether HO activity was facilitating the intra- or extravasation
event, 4T1-eGFP cells were injected i.v. into mice receiving
SnMP. Abrogation of HO-1 activity did not compromise the
ability of 4T1 cells to colonise the lung (Fig. 6j), suggesting that
SnMP might have targeted the intravasation event at the primary
tumour site rather than extravasation and colonisation in the
lung. As IL-6 was a regulator of the FAP+ HO-1+ TAM phe-
notype in this model, we analysed pulmonary metastasis in 4T1
tumours grown in Il6−/− mice, and in agreement, found sig-
niﬁcantly fewer metastases in the absence of host-derived IL-6
Fig. 2 FAP+ HO-1+ macrophages represent a wound healing response phenotype. a Heat map of raw gene expression values from splenic-derived M-CSF
basal macrophages (M0) and 4T1 TAMs (n= 4 per condition). b Gene ontology enrichment analysis of M0 vs. 4T1 TAMs, showing selected pathways of
interest that were signiﬁcantly enriched. c–e Skin sections stained using DAPI (nuclei, blue) and antibodies against F4/80 (green), FAP (yellow) and HO-1
(red). c Image of healthy skin taken using a ×40 objective. d Image of wounded skin taken using a ×4 objective 6 days post wounding (pw). e High
magniﬁcation image of example F4/80+ FAP+ HO-1+ cells found in the granulation tissue; arrow marks cell of interest. f, g Quantiﬁcation of F4/80+ cells
normalised to area (f) and percentage of F4/80+ cells that co-expressed FAP and HO-1 (g) as an average of multiple ﬁelds of view in the healthy dermis
and in the respective area of the wound environment (n= 6 mice per condition). Statistics were performed to compare each condition to healthy dermis.
h Volcano plots showing changes in cytokine gene expression in skin in response to wounding using a 1 mm punch biopsy needle28. Genes marked in red
represent cytokines most highly induced 12 h (left) and 24 h (right) pw (P ≤ 0.05; Log2 (fold change) ≥4). i Expression levels of the indicated genes
(h) over the duration of the wound response to a 1 mm punch biopsy needle28. j mRNA expression of the indicated cytokine genes relative to the
housekeeping gene Tbp in healthy mammary gland (n= 6) and late stage (>20 day post inoculation) 4T1 (blue) and E0771 (black) tumours (n= 6). kM0-
subtracted gene expression from 4T1 TAMs, displaying selected genes of interest (n= 4). Bar charts represent mean+ s.d. *P < 0.05, **P≤ 0.01
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(Fig. 6k), demonstrating that IL-6 played a key role in the process.
IL-6 has been described to augment IL-4R signalling in macro-
phages49, which can polarise macrophages to facilitate tumour
cell invasiveness7,50, however pulmonary metastasis was unaf-
fected in 4T1 tumours grown in Il4r−/− mice (Fig. 6l and Sup-
plementary Figure 7d). There were also signiﬁcantly fewer
pulmonary metastases in mice bearing E0771 tumours that were
devoid of FAP+ HO-1+ TAMs when compared to mice bearing
4T1 tumours (Fig. 6m and Supplementary Figure 7e). These data
suggest that HO-1+ activity by FAP+ TAMs could play a role in
the metastatic spread of tumours, most likely by promoting
tumour cell intravasation due to their prevalence in the perivas-
cular region.
Macrophage HO-1 activity facilitates tumour cell TEM. To
investigate whether the IL-6/HO-1 axis might directly facilitate
transendothelial migration of tumour cells, BMDM were exposed
to IL-6 to upregulate HO-1 expression (Fig. 4a) and co-cultured
with 4T1 tumour cells on an endothelial cell layer in an in vitro
transwell assay (Fig. 6n and Supplementary Figure 8a, b). IL-6-
exposed macrophages (M(IL-6)) strongly enhanced transen-
dothelial migration of tumour cells, which was HO-1 dependent
as SnMP completely abrogated this effect (Fig. 6o). CO, a by-
product of HO activity, is a biologically active molecule that can
play key roles in cytoprotection through modulating cellular
signalling, the mitochondrial electron transport chain, and the
generation of reactive oxygen species51. To exclude the possibility
that SnMP might have affected the viability of the 4T1 cells or
macrophages, thereby reducing the number of live migrated cells,
4T1 tumour cells and macrophages were incubated with
increasing doses of SnMP. However, SnMP did not affect the
viability of either 4T1 cells or macrophages at any dose or time
point tested (Supplementary Figure 8c, d). Also, neither M(IL-6)
cells nor SnMP treatment affected the permeability of the endo-
thelial monolayer (Fig. 6p and Supplementary Figure 8e, f),
suggesting that HO-1 plays an active role in the migration of the
tumour cells through the endothelial cell layer. We assessed
which by-product of haem catabolism could account for these
effects. Exposure of 4T1 cells to biliverdin or Fe did not increase
cellular migration; however, exposure to CO signiﬁcantly
increased the number of 4T1 cells migrating across the endo-
thelial barrier (Fig. 6q), which was also independent of the per-
meability of the endothelial monolayer (Supplementary
Figure 8g). These data suggest that IL-6 stimulated the HO-1-
dependent production of CO by macrophages, thereby promoting
tumour cell transendothelial migration.
These observations collectively prompt the need to consider
evaluating cancer patients for an innate wound healing-like
response, for which the cytokine milieu can be informative. This
study also provides a potential therapeutic approach using SnMP,
a drug that has already been used in the clinic46,47, to target the
ability of FAP+ HO-1+ TAMs to facilitate tumour cell
intravasation and spread of the disease (Fig. 7).
Discussion
In this study, we have demonstrated that tumours exploit mac-
rophages into adopting a phenotype similar to that generated by
macrophages found in the granulation tissue during the inﬂam-
matory response to wounding, which is characterised by
Gastric cancer
O
S 
(%
)
150500
Time (months)
100
100
80
60
40
20
0
**
High HWCs
Low HWCs
Ovarian cancer
O
S 
(%
)
150500
Time (months)
100
100
80
60
40
20
0
High HWCs
Low HWCs
200
****
Breast cancer
O
S 
(%
)
Time (months)
100
80
60
40
20
0
****
High HWCs
Low HWCs
150500 100 200 250 300
O
S 
(%
)
150500
Time (months)
100 200
100
80
60
40
20
0
****
High HWCs
Low HWCs
Lung cancera b
c d
Fig. 3 The presence of a healing wound-like cytokine response is associated with poor prognosis in human cancers. Kaplan–Meier survival curves showing
overall survival (OS) with high (red) and low (black) tumour expression of HWCs (SPP1, IL1B and IL6) for patients with a breast cancer (n= 996 in HWCslo
group and 406 in HWCshi group), b lung cancer (n= 622 in HWCslo group and 1304 in HWCshi group), c gastric cancer (n= 313 in HWCslo group and
280 in HWCshi group) and d ovarian cancer (n= 843 in HWCslo group and 813 in HWCshi group). **P≤ 0.01, ****P≤ 0.0001
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05346-7 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:2951 | DOI: 10.1038/s41467-018-05346-7 |www.nature.com/naturecommunications 7
3D collagen + M-CSF
+IL-6
Time
(min)
β-actin
FAP
EGR1
0
4T
1
E0
77
1
4T
1
E0
77
1
20
40
60
80
0
50
100
150
200
250
0
1
2
3
4
m
R
N
A 
fo
ld
 re
la
tiv
e 
to
 T
bp
Il6
Col1a1
****
Pre –
+ M-CSF
0
100
200
300
400
Hmox1
F4
/8
0
FSC-A
97%
M-CSF + IL-6
FAP
4T1 E0771Wound
4T
1 
ce
lls
CA
Fs
N
eu
tro
ph
ils
M
on
oc
yt
es
M
ac
ro
ph
ag
es
CD
45
+
 
o
th
er
100 μm 100 μm 100 μm
6
8
10
12
14
16
18
20
22
Se
ru
m
 c
on
ce
nt
ra
tio
n 
(ng
/m
l)
IL-6
IL-4 IL-6Pre
M-CSF
β-actin
HO-1
M
ou
se
 
IL-6Pre
M-CSF
β-actin
HO-1
H
um
an
N
o 
tu
m
ou
r
4T
1
E0
77
1
G
-C
SF
IL
-1
β
IL
-4
IL
-6
O
PN
O
SM
0
1
2
3
4
Pr
e
IL
-6–
+ M-CSF
HO-1
*
*
R
el
at
iv
e 
ex
pr
es
sio
n 
(A
U)
**
Human
%
 o
f t
ot
al
 a
re
a
SHG
****
m
R
N
A 
fo
ld
 re
la
tiv
e 
to
 T
bp
28
kDa
25
64
kDa
250
m
R
N
A 
fo
ld
 re
la
tiv
e 
to
 T
bp
15 30 120 24060 15 30 120 24060
IFNγ +
LPS
a b c d
e f g
h i
j k
Fig. 4 IL-6 and collagen drive FAP+ HO-1+ TAM differentiation in vitro. a Hmox1 mRNA expression relative to the housekeeping gene Tbp in bone marrow-
derived (BM) cells before (Pre) and after macrophage differentiation in the presence of indicated cytokines at 50 ng/ml for 72 h (n= 2 wells;
representative of three experiments). b Western blot for HO-1 and the loading control β-actin in BM cells before (Pre) and after 72 h culture in the
presence of 50 ng/ml M-CSF with/without 50 ng/ml IL-4, IFNγ+ LPS or IL-6 (top) and human peripheral blood (PB)-derived macrophages before (Pre)
and after 72 h culture in the presence of 50 ng/ml M-CSF with/without 50 ng/ml IL-6 (bottom). c Quantitation of HO-1 expression in human PB-derived
macrophages from individual healthy volunteers (n= 5) as described in b. d Serum IL-6 concentrations in tumour-free mice and in those bearing late stage
(>20 days post inoculation) 4T1 (black) or E0771 (white) tumours (n= 5) as determined by ELISA. e Representative Il6mRNA expression relative to Tbp in
FACS-sorted tumoural cell populations from a 4T1 tumour (n= 2 wells, representative of duplicate experiments). f Representative gating, purity and FAP
surface expression of BM cells cultured for 72 h in the presence of 50 ng/ml M-CSF and IL-6. g Representative western blot analysis for FAP (top), EGR1
(middle) and β-actin (bottom) in BM cells cultured for 72 h with 50 ng/ml M-CSF with/without 50 ng/ml IL-6, and subsequently incubated for indicated
times on 3D murine type I collagen. h, i Representative images of second-harmonic generation (SHG) imaging of ﬁbrillar collagen in frozen sections of
wounded skin (h) and of 4T1 and E0771 tumours (i). j Quantitation of SHG signal in 4T1 and E0771 tumours (n= 12 tumours (>20 days post inoculation) in
each group; average across multiple ﬁelds of view). k Col1a1 mRNA expression relative to Tbp in 4T1 (n= 16) and E0771 (n= 18) tumours (>20 days post
inoculation). Bar charts are presented as mean+ s.d. *P≤ 0.05, **P≤ 0.01, ****P≤ 0.0001
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05346-7
8 NATURE COMMUNICATIONS |  (2018) 9:2951 | DOI: 10.1038/s41467-018-05346-7 | www.nature.com/naturecommunications
co-expression of FAP and HO-1, which in the context of cancer
can facilitate transendothelial migration of tumours cells.
Harold Dvorak’s seminal observation that tumours and healing
wounds display inherent similarity18, is now a concept which is
deeply embedded in our understanding of the stromal response in
cancer52. Gene signatures associated with ‘healing wounds’ have
previously been identiﬁed in breast cancer and have been linked
to poor prognosis53,54. In the present study, we speciﬁcally
describe cytokine genes that are associated with the inﬂammatory
phase of a wound response, comprising Il1B, IL6 and SPP1, which
are upregulated in the inﬂammatory phase of both human and
mouse wounds. Expression levels of these three genes were suf-
ﬁcient to segregate patients with poor prognosis for breast, lung,
gastric and ovarian cancer, highlighting the prognostic sig-
niﬁcance in cancer progression.
Very little is known about the FAP+ HO-1+ subset of
macrophages, which can be found in both human and murine
breast tumours. Here, we identiﬁed their appearance as a
wound healing response phenotype associated with the gran-
ulation tissue, which provides signiﬁcant biological insight
and context to understand their origin and function. FAP+
HO-1+ macrophages ﬁrst appear within the granulation in the
initial days after wounding, during the acute inﬂammatory
phase of the response, however their presence is maintained
during the wound healing response. In the current study we
investigated the dorsal wound; however, the cytokine response
can also be dictated, and ﬁne-tuned, by the anatomical loca-
tion of the wound site, such as was observed between the skin
and mucosal surface28. The presence of FAP+ HO-1+ mac-
rophages at other wound sites, and their speciﬁc role within
the granulation tissue, although not covered by the current
study, remain important questions to consider.
We have demonstrated IL-6 to be a key regulator of the FAP+
HO-1+ macrophage phenotype, and this cytokine is also
expressed directly by the macrophages in 4T1 tumours. IL-6 has
the potential to regulate HO-1 expression through both autocrine
and paracrine signalling, concurrently licensing FAP expression
in macrophages in a collagen-rich microenvironment. FAP is a
dipeptidyl peptidase capable of degrading type I collagen11,12,
which is coherent with our observation that FAP expression is
induced in part by exposure to type I collagen, its substrate. Type
I collagen is the major collagen of the dermal layer of the skin40,
and its expression in cancer has been associated with poor
prognosis in patients55. FAP has long been associated with
tumour progression and wound healing in animal models56,57,
and is also associated with poor clinical outcome in patients with
cancer58,59. Although in the current study, FAP has only been
used as a marker, its expression could feasibly facilitate a mac-
rophage’s ability to migrate through the collagen networks found
in the dermis and in the tumour microenvironment, similar to
that demonstrated for FAP-expressing ﬁbroblasts60. FAP
expression on TAMs could serve as a marker of a regenerative-
like tumour microenvironment.
TAMs have been demonstrated to play a critical role in meta-
static spread7,61, and tumour cells and TAMs are closely associated
during intravasation43. A well-characterised example of this
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interaction is through a paracrine loop involving M-CSF released
from tumour cells, and epidermal growth factor (EGF) released by
TAMs62. The importance of the M-CSF/EGF paracrine loop in
metastasis has been clearly demonstrated by mammary xenograft
models using a conditional knockout of CSF-162. We demonstrate
that HO-1 expression, which is upregulated in response to the
HWC IL-6, plays a role in facilitating transendothelial migration of
tumour cells, thereby supporting their metastatic spread. HO-1
expression also correlates with metastasis in human cancer63 and
has previously been implicated with metastasis in murine mod-
els64. While our results indicate that FAP+ HO-1+ TAMs facilitate
tumour cell intravasation, supported by their presence in the
perivascular region of the tumour, others have also described a
role for lung-resident HO-1+ macrophages in facilitating the
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extravasation of metastatic tumour cells entering the lung64.
Despite our results suggesting that lung colonisation of 4T1 cells
was HO-independent, these ﬁndings highlight the broader phy-
siological role of HO activity in transendothelial migration, which
is exploited by different tumours.
We have demonstrated that the haem catabolite CO, which is
capable of modulating cellular signalling and functions64–68, was
capable of facilitating transendothelial migration of 4T1 cells,
which is consistent with previous reports64. The mechanism
through which this was achieved was independent of the role of
HO-1 in vasorelaxation69 as HO-1-expressing macrophages had
no observable effect on the permeability of an endothelial layer.
HO-1 has also been demonstrated to play an active role in injury
repair70, to facilitate wound closure71 and to improve the
migratory potential of keratinocytes71, which may explain their
ability to facilitate transendothelial migration of 4T1 cells.
In 4T1 tumours, the TAMs were the major, but not the only
stromal source of IL-6. Interestingly, macrophages have been
demonstrated to secrete IL-6 when co-cultured with 4T1 cells72,
suggesting that TAMs can be coerced into adopting this response
by a direct interaction. There are characterised interactions
which can result in IL-6 expression by macrophages73,30,
although the speciﬁc interaction was not investigated in
this current study, it is an important question to resolve. How-
ever, this study prompts the wider need to consider the impor-
tance of IL-6 in the macrophage response in both wound healing
and cancer.
In the present study, we have demonstrated that FAP+ HO-1+
TAMs found in the microenvironment of human and murine
breast cancers represent an innate wound healing response phe-
notype. Their phenotype is analogous to the response of macro-
phages found in the granulation tissue after wounding. FAP+ HO-1
+ TAMs have previously been demonstrated to play a fundamental
role in immune suppression in the tumour microenvironment3, a
role also attributed to the expression of HO-1 in the wound74.
Furthermore, we demonstrate that HO-1 expression by these
macrophages can facilitate metastatic spread. These data collectively
suggest that FAP+ HO-1+ macrophages reﬂect a potent pro-
tumorigenic TAM phenotype. However, the full diversity of
cancers and other diseases in which FAP+ HO-1+ macrophages
can play a role has yet to be established. This study has started to
shed light on the contextual origin of FAP+ HO-1+ TAMs and
their exploitation by the tumour to facilitate metastatic spread of the
disease. Moreover, we demonstrate that pharmacological inhibition
of HO-1 is a viable therapeutic strategy to prevent their role in
metastasis.
Methods
Mice. Balb/c mice WT and homozygous null (−/−) for Il6 or Il4r were obtained
from Charles River. Balb/c Rag2−/− were a gift from Professor Adrian Hayday
(KCL). All mice used for experiments were female and randomly assigned to non-
blinded treatment groups. Cohort sizes were informed by prior studies3,15.
Superﬁcial wounding of the skin was performed using an 8 mm punch biopsy
needle (Stiefel Instruments) under analgesia and general anaesthesia. Experiments
were performed at least in duplicate;. The use of animals was approved by the
Ethical Review Committee at King’s College London and the Home Ofﬁce, UK.
Cell lines. 4T1 mammary adenocarcinoma cells6 and 3B-11 endothelial cells were
obtained from ATCC. E0771 mammary adenocarcinoma cells20,21 were a gift from
Prof. Anne Ridley (King’s College London). Cell lines were conﬁrmed to be
mycoplasma free using the MycoAlert Mycoplasma Detection Kit (Lonza) and
were cultured in RPMI 1640 (Gibco) supplemented with 10% FCS.
Transduction of cell lines. The pMIG retroviral vector was a gift from Prof.
Douglas Fearon, Cold Spring Harbor Laboratory, New York, and was modiﬁed to
contain Click Beetle luciferase and enhanced green ﬂuorescent protein (eGFP)
separated by a viral P2A sequence. Click Beetle luciferase cDNA was cloned from
the vector pCBG99 (Promega) using forward primer (P1) 5′-GTGA
AGCGTGAGAAAAATGTCA-3′ and reverse primer (P2) 5′-TGAAGTTAGTA
GCTCCGCTTCCACCGCCGGCCTTCTCCAA-3′, which also incorporated a P2A
sequence overhang. Click Beetle luciferase cDNA was joined to P2A using overlap
PCR with a synthetically derived P2A cDNA sequence (Integrated DNA Tech-
nologies) using P1 and reverse primer (P3) 5′-CTCCTCGCCCTTGCTCACA
GGTCCAGGGTTCTCCTCC-3′, which also incorporated an eGFP sequence
overhang. eGFP cDNA was cloned from the vector pEGFP-N1 using forward
primer (P4) 5′-GTGAGCAAGGGCGAGGAG-3′ and reverse primer (P5) 5′-C
TTGTACAGCTCGTCCATGC-3′. Click Beetle luciferase/P2A and eGFP cDNA
were joined using PCR with primers P1 and P5. Finally, Xho1 and HindIII
restriction enzyme sites were added to the reporter construct cDNA using PCR
with the respective forward 5′-CTCGAGATGGTGAAGCGTGAGAAAA
ATGTCA-3′ and reverse 5′-AAGCTTTTACTTGTACAGCTCGTCCATGC-3′
primers. The PCR product was then subcloned using Zero Blunt™ Topo™ Kit
(Thermo Fisher Scientiﬁc), and subsequently inserted into pMIG using the
restriction enzymes XhoI and HindIII (New England Biolabs) and T4 DNA ligase
(Thermo Fisher Scientiﬁc). Full-length murine Csf3, the gene for G-CSF, was
cloned using PCR with forward primer 5′-TTAGCGATCAAGATCTACCATG
GCTCAACTTTCTGCCCAGAG-3′ incorporating a BglII site, and reverse primer
5′-CGTGAATCGACTCGAGCTAGGCCAAGTGGTGCAGAG-3′ incorporating a
XhoI site, from puriﬁed 4T1 tumour cell mRNA which had been converted to
cDNA using the RT2 ﬁrst strand kit (Qiagen). Csf3 cDNA was subsequently
inserted into pMIG using the restriction enzymes BglII and XhoI (New England
Biolabs) and T4 DNA ligase (Thermo Fisher Scientiﬁc). These restriction enzyme
sites maintained an endogenous Thy1.1 reporter element within the pMIG vector.
Empty vector containing Thy1.1 alone was used as a control. Retroviral particles
were produced, and 4T1 and E0771 cells were transduced as previously described15.
eGFP+ 4T1 and Thy1.1+ and Thy1.1/G-CSF+ E0771 cells were selected by ﬂow
cytometry for their expression of eGFP or Thy1.1, respectively, and subsequently
expanded in culture. G-CSF was conﬁrmed to be secreted using the mouse G-CSF
ELISA set (Insight) according to the manufacturers’ protocol on conditioned media
from the cell lines.
Fig. 6 Perivascular FAP+ HO-1+ macrophages can facilitate transendothelial migration of tumour cells through their HO activity. a Representative images
of frozen sections of a 4T1 tumour stained with DAPI (nuclei; blue) and antibodies against F4/80 (green) and HO-1 (red); functional vasculature was
labelled in vivo using dextran-FITC (yellow). b Quantiﬁcation of F4/80+ TAMs co-expressing HO-1 in avascular and perivascular regions (n= 12 sections
across four tumours in each group). c Tumour growth curves of mice bearing established 4T1 tumours treated with vehicle (blue) or 25 μmol/kg/day
SnMP (orange) (n= 6), arrow marks the initiation of treatment. dMetastatic nodules on the lung surface of mice bearing 4T1 tumours treated with vehicle
(n= 16) or 25 μmol/kg/day SnMP (n= 15) at day 24 post inoculation of tumour cells (data from three independent experiments presented). e–i 4T1
tumours or lungs in mice treated with vehicle (blue) or SnMP (orange) as described in c were analysed. e Abundance of TAMs, monocytes and neutrophils
in enzyme-dispersed tumours (n= 5 per condition). f Representative ﬂow cytometry gating strategy for MAMs. g Representative surface FAP staining
(blue) and isotype control staining (grey shaded) of MAMs in the lungs of 4T1 tumour-bearing mice (day 24). h, i Abundance of lung neutrophils (h) and
MAMs (i) (n= 4 per condition). j Representative ﬂow cytometry gating strategy (left) and abundance (right) of 4T1-eGFP cells in enzyme-digested lungs
48 h after i.v. injection of 4T1-eGFP in mice treated with vehicle (blue) or 25 μmol/kg/day SnMP (orange) (n= 10 mice). k–m Abundance of metastatic
nodules on the surface of lungs in mice bearing 4T1 tumours grown in WT (n= 17) and Il6−/− (n= 9) mice (k), WT (n= 12) and Il4r−/− (n= 8) mice (l),
or in syngeneic mice bearing 4T1 (n= 9) or E0771 (n= 9) tumours (m). n Schematic representation of the transendothelial migration assay; EC endothelial
cells. o, p Relative transendothelial migration of 4T1-eGFP cells (o) and permeability of the EC layer to albumin (p) in the presence or absence of HO-1+
Ly6Chi monocyte-derived macrophages (M(IL-6)) with/without 25 μM SnMP (orange) (n= 4 wells; representative of duplicate experiments) over a 24 h
period. q Relative transendothelial migration of 4T1-eGFP cells in the absence (n= 12) or presence of 20 μM Iron (II) chloride (n= 8), 5 μM biliverdin (n=
8) or 250 ppm CO (n= 3) (pooled data from separate experiments). Bar charts represent mean+ s.d. *P < 0.05, ** P < 0.01, ****P < 0.0001
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Tumour studies. 4T1 or E0771 cells (2.5 × 105 in 100 μl RPMI) were orthotopically
implanted by subcutaneous injection into the mammary fat pad of female mice that
were 6–8 weeks of age. The sizes of the subsequent tumours were determined as
previously described15. Sn (IV) mesoporphyrin IX dichloride (SnMP; Frontier
Scientiﬁc) was prepared freshly on the day of injection as previously described3 and
administered daily at 25 μmol/kg by intraperitoneal injection. Blood samples were
taken from mice in EDTA-coated Microvette™ tubes (Sarstedt). Plasma was
extracted from blood samples by centrifugation at 2000 × g for 5 min and IL-6
quantitated using the mouse IL-6 ELISA set (Insight Biotechnology) according to
the manufacturer’s protocol. Tumour tissue and other organs were enzyme-
digested to release single cells as previously described15. Spontaneous lung meta-
static surface nodules were quantiﬁed by manual counting in a blinded manner.
In vivo metastasis assay. Wild-type Balb/c mice that were 6–8 weeks of age were
treated with 25 μmol/kg/day SnMP or vehicle control from 72 h prior to tumour
cell challenge. On day zero, 5 × 105 4T1-eGFP cells in 200 μl Dulbecco’s PBS
(Thermo Fisher Scientiﬁc) were injected intravenously via the tail vein. After 48 h,
mice were killed and the lungs were dissociated by enzyme dispersion to release a
single-cell suspension as previously described15. 4T1-eGFP cells that had colonised
the lung were identiﬁed by their eGFP expression and quantiﬁed using counting
beads by ﬂow cytometry analysis.
Magnetic-bead isolation of macrophages and monocytes. Single cells released
frommurine tumour tissue using enzyme dispersion, or crushed from a spleen of a 4T1
tumour-bearing mouse, were pelleted by centrifugation at 500 × g and red blood cells
(RBC) were lysed using RBC lysis buffer (eBioscience) according to the manufacturer’s
protocol. Human peripheral blood mononuclear cells (PBMCs) were obtained from
anonymised human buffy coats as supplied by the NHS Blood and Transplant
(London, UK). Buffy coats were diluted 1:2 with calcium and magnesium-free PBS
(Gibco), then the PBMC fraction was isolated using a Lymphoprep (Axis-Shield)
density gradient spun at 800 × g for 30min at RT. Cells were pelleted and resuspended
in PBS containing 2mM EDTA, 1% FCS. All subsequent steps were performed on ice
for 30min unless otherwise stated. Murine Fc receptors were blocked using 5 μg/ml
anti-CD16/32 (2.4G2, Tonbo Biosciences) prior to staining with F4/80 PE (BM8; to
isolate macrophages) or Ly6C PE (HK1.4; to isolate monocytes) at 1 µg/ml, followed by
anti-PE MicroBeads (Miltenyi Biotec). CD14+ human monocytes were incubated
directly with anti-human CD14 MicroBeads (Miltenyi Biotec). Both human and
murine cells were subsequently isolated using a MidiMacs separator and LS columns
(Miltenyi Biotec) according to the manufacturer’s protocol.
In vitro-derived macrophages. Murine bone marrow (BM) was ﬂushed from the
femur and tibia using a syringe and needle, and RBCs were lysed using RBC lysis
buffer (eBioscience). Complete murine BM, or splenic murine Ly6C+ cells or
PBMC-derived human CD14+ MACS-sorted monocytes were plated in RPMI
10% FCS, 1× penicillin/streptomycin (Sigma-Aldrich), 50 ng/ml recombinant
murine (Bio-techne) or human (Peprotech) M-CSF at 1 × 106 cells/well on 6-well
plates for subsequent mRNA and protein analyses. Where viable macrophages
were required for ongoing experiments, cells were plated at 5.5 × 106 cells on 6
cm non-tissue culture-treated plates. Additional murine cytokines, IL-4 (Bio-
techne) and IFN-γ (Bio-techne), human IL-6 (Peprotech), or LPS (Sigma-
Aldrich) were added where indicated in the ﬁgure legends at 50 ng/ml unless
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stated otherwise. After 72 h in culture, macrophage purity was assessed by ﬂow
cytometry. Macrophages differentiated in the presence of M-CSF only are
referred to as M0 cells, and macrophages differentiated in the presence of M-CSF
and IL-6 as M(IL-6) cells.
Collagen matrix assembly. A collagen matrix was prepared by mixing 2 mg/ml
type I collagen (BIO RAD) in 50 mM acetic acid with 1.5 parts ice cold RPMI, 10%
FCS, 33.3 mM NaOH, and 200 μl was transferred to each well of a 24-well plate for
polymerisation for 30 min at 37 °C. Differentiated macrophages (described above)
were re-plated onto the collagen matrix in RPMI, 10% FCS, 50 ng/ml recombinant
murine M-CSF (Bio-techne) at 2 × 105 cells/well.
Transendothelial migration assays. Transendothelial migration assays were
performed as described previously8 with modiﬁcations. Brieﬂy, transwell inserts
with 8 μm pore size (Corning) were coated with 125 µg/ml Matrigel (Corning). An
endothelial barrier was established by culturing 2 × 104 3B-11 endothelial cells in
RPMI with 10% FCS on the Matrigel-coated inserts. After 72 h in culture, medium
was replaced with RPMI, 0.5% FCS containing 2 × 104 4T1-eGFP cells, and RPMI,
10% FCS was added to the bottom chamber. Where indicated, 2 × 104 splenic-
derived M(IL-6) macrophages were added to the upper chamber and allowed to
adhere for 2 h in RPMI, 10% FCS. The media was removed and 2 × 104 4T1-eGFP
cells were added in RPMI, 0.5% FCS. These experiments were performed in the
presence or absence of 50 ng/ml IL-6 and M-CSF, 25 μM SnMP, 20 μM iron (II)
chloride (Sigma-Aldrich), 5 μM biliverdin hydrochloride (Sigma-Aldrich), or a gas
mix of 250 ppm CO, 5% CO2, N2 balance (BOC) in a hypoxia incubator chamber
(Stemcell Technologies). After 72 h of incubation at 37 °C, cells were removed from
the upper chamber using a cotton swab. Transmigrated cells were dissociated from
the bottom of the transwell using enzyme-free dissociation buffer (Thermo Fisher
Scientiﬁc). Collected cells were mixed with AccuCheck counting beads (Thermo
Fisher Scientiﬁc) and 7-amino actinomycin D (7AAD) (Sigma-Aldrich) prior to
analysis by ﬂow cytometry. The permeability assay was performed as described
previously8. In brief, permeability was measured using Evans Blue-conjugated
bovine serum albumin (BSA) (4%) in PBS, placed into the upper chamber of a
Matrigel-coated transwell insert with 0.4 μm pore size (Corning), and phenol red-
free RPMI, 10% FCS was added to the bottom chamber. Presence of Evans Blue-
BSA in the bottom chamber was assessed at indicated time points by absorbance at
620 nm on a NanoDrop™ 2000 spectrophotometer (Thermo Fisher Scientiﬁc).
Cell viability MTT assays. Bone marrow-derived macrophages (BMDM) were
plated at a density of 1 × 106 cells per well of a 6-well plate in RPMI 1640 (Thermo
Fisher) supplemented with 10% FCS, 10 ng/μl M-CSF (Bio-techne) and penicillin/
streptomycin (Sigma-Aldrich); 4T1 cells were plated at a density of 3.5 × 105 (24 h
assay) or 1 × 103 (4 day assay) in 24-well tissue culture plates in RPMI, 10% FCS.
Cells were given 24 h to attach, and were then incubated with media containing
either SnMP or vehicle. At the indicated time point, media was exchanged with
phenol-free RPMI (Sigma-Aldrich) supplemented with 10% FCS and 0.5 mg/ml
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reagent and
incubated for 1 h. MTT-RPMI media was aspirated and the formazan crystals
(generated from metabolised MTT) were solubilised with dimethyl sulfoxide and
the absorbance measured at 538 nm on a Fusion alpha-FP spectrophotometer
(Perkin-Elmer) or NanoDrop™ 2000 spectrophotometer (Thermo Fisher Scientiﬁc).
All values were normalised to the vehicle control-treated wells.
Flow cytometry and cell sorting. Flow cytometry was performed as previously
described15. The following antibodies were purchased from eBioscience and were
used at 1 µg/ml unless stated otherwise: CCR2 APC (475301; 1:10; Bio-techne),
CD11b Brilliant Violet 510™ (M1/70; Biolegend®), CD11b eFluor®450 (M1/70),
CD11c APC (N418), CD14 APC (Sa2-7), CD45 APC-eFluor®780 (30-F11), F4/80
APC/PE/FITC (BM8), IL-4R PE (1:10; Bio-techne), Ly6G FITC (1A8; Biolegend®),
MHCII APC (M5/114.15.2), MMR APC (1:10; Bio-techne), Ly6C PE (HK1.4),
Thy1.1 eFluor 450 (HIS5a), Thy1.2 eFluor 450 (53-2.1). Where stated, the fol-
lowing corresponding isotype control antibodies at equivalent concentrations to
that of the test stain were used within ﬂuorescence minus one staining panels: goat
IgG APC and PE (Bio-techne), rat IgG2b APC and eFluor® 450 (eB149/10H5), rat
IgG2a APC and PE (eBR2a) and Armenian Hamster IgG APC (eBio299Arm). FAP
was stained as previously described15. Dead cells and red blood cells were excluded
using 1 µg/ml 7AAD (Sigma-Aldrich) and anti-Ter-119 PerCP-Cy5.5 (Ter-119),
respectively. Flow cytometry was performed on a BD FACS Canto II (BD Bios-
ciences) or cells were sorted for subsequent analyses using a BD FACSAria (BD
Biosciences). Data were analysed using FlowJo software (Freestar Inc.). Cell
populations were distinguished based upon the following surface characteristics:
CD45+ (immune cells), CD11b+ F4/80hi (macrophages), CD11b+ Ly6G− Ly6C+
(monocytes), CD11b+ Ly6G+ (neutrophils), CD3ε+ (T cells), CD3ε+ CD4+ (CD4
+ T cells), CD3ε+ CD8α+ (CD8+ T cells), CD19+ (B cells), CD45− Thy1+ (CAFs),
CD45− CD31+ (endothelial cells), CD45− Thy1− CD31− (tumour cells) and CD45
+ CD11b+ Ly6C−Ly6G− F4/80hi (MAMs).
Western blot. Cells were lysed and SDS-PAGE/western blots were conducted as
previously described6 with the following primary antibodies at 1:1000 unless stated
otherwise: HO-1 (mouse: EP1391Y, Origene; human: 41211, Bio-techne), FAP
(AF3715, Bio-techne), EGR1 (15F7, Cell Signalling Technology), β-actin, 1:5000
(Abcam) and detected using the following horseradish peroxidase-conjugated
secondary antibodies: goat anti-rabbit IgG (H+L), 1:25,000 (Thermo Fisher Sci-
entiﬁc), anti-sheep IgG, 1:2500 (Bio-Techne). Protein bands were detected using
Luminata™ Crescendo Western HRP substrate (Millipore) and CL-XPosure™ Film
(Thermo Fisher Scientiﬁc). Densitometry was performed using ImageJ software.
The uncropped western images used in this paper can be seen in Supplementary
Figure 4.
Quantitative real-time PCR. mRNA was extracted and quantitative real-time
PCR was performed as previously described3 using the following primers/
probes purchased from Thermo Fisher Scientiﬁc: Csf3 Mm00438335_g1,
Col1a1 Mm00801666_g1, Col3a1 Mm01254476_m1, Csf3 Mm00438335_m1,
Fn1 Mm01256744_m1, Hmox1 Mm00516005_m1, Il1b Mm00434228_m1,
Il4 Mm00445259_m1, Il6 Mm00446190_m1, Il10 Mm01288386_m1,
Il13 Mm00434204_m1, Il24 Mm00474102_m1, Osm Mm01193966_m1, Spp1
Mm00436767_m1, Tbp Mm01277045_m1, Tnc Mm00495662_m1. Expression
is represented relative to the housekeeping gene Tata-binding protein (Tbp). An
extracellular matrix and adhesion molecule RT2 proﬁler PCR array (PAMM-
013Z; Qiagen) was also utilised, for this mRNA from 4T1 and E0771 tumour
tissue was converted to cDNA using RT2 ﬁrst strand kit (Qiagen), and assays
run using RT2 SYBR Green ROX qPCR Mastermix (Qiagen) according to the
manufacturer’s protocol. Gene expression was measured using an ABI 7900HT
Fast Real Time PCR instrument (Thermo Fisher Scientiﬁc).
Illumina microarray and bioinformatics analysis. Puriﬁed mRNA for the
respective macrophage populations was isolated using the PureLink® RNA Mini Kit
(Ambion) according to the manufacturer’s protocol. The purity of the isolated
mRNA was assessed using a NanoDrop™ 2000 spectrophotometer (Thermo Fisher
Scientiﬁc) and the quality and integrity using an Agilent 2100 Bioanalyzer (Agilent
Technologies). mRNA was converted to cDNA, then subsequently ampliﬁed using
the Ovation® PicoSL WTA system V2 (NuGen), biotinylated using the Encore®
BiotinIL Module (NuGen) and then hybridised to MouseWG-6 V2.0 Beadchip
microarray (Illumina). Following hybridisation, the arrays were washed, blocked and
stained with streptavidin-Cy3 using the whole-genome gene expression direct
hybridisation assay (Illumina). Microarrays were run on an Illumina iScan system,
raw ﬂuorescence signals were collected using GenomeStudio (Illumina), and the data
imported into Partek Genomics Suite for analysis. Background was subtracted from
the raw data and ﬂuorescence signals were normalised using the quantiles method75.
Immunoﬂuorescence. Sections of fresh frozen human breast carcinoma (all
identiﬁed as grade 3 invasive ductal carcinoma, two basal-like and one HER2+),
mouse mammary tumours or wounded skin embedded in OCT were ﬁxed in 4%
paraformaldehyde in PBS (Gibco) for 10 min at RT. Immunoﬂuorescence was
performed as previously described15 with the inclusion of 0.2% Triton X-100 in the
blocking buffer. The following antibodies were used at 1:100 dilutions unless stated
otherwise: F4/80 (C1:A3-1, Bio-RAD), HO-1 (EP1391Y, Origene) or HO-1 (10701-
I-AP; Proteintech Group), FAP (AF3715, Bio-techne), EGR1, 1:50 (15F7, Cell
Signalling Technology), CD14 (61D3, eBioscience), CD11b (ICRF44, eBioscience).
Primary antibodies were detected using Cy™3 donkey anti-sheep IgG, 1:100
(Jackson ImmunoResearch, reconstituted at 1 mg/ml), or the following donkey IgG
antibodies purchased from Thermo Fisher Scientiﬁc and used at 1:200: AlexaFluor®
488 anti-rabbit IgG, AlexaFluor® 488 anti-rat IgG, AlexaFluor® 647 anti-mouse
IgG, AlexaFluor® 647 anti-rabbit IgG. Viable blood vessels were visualised in mice
through i.v. injection of FITC-conjugated dextran (MW20,000, Sigma-Aldrich) 30
min prior to sacriﬁce. Nuclei were stained using 1.25 μg/ml 4′,6-diamidino-2-
phenylindole, dihydrochloride (DAPI) (Thermo Fisher Scientiﬁc). Images were
acquired using a Nikon Eclipse Ti-E Inverted spinning disk confocal microscope
system and associated NIS Elements software, and total, nuclear and cytoplasmic
staining were quantiﬁed using ImageJ. Perivascular TAMs were analysed as pre-
viously described9 with modiﬁcations. F4/80+ cells present within a 75 μm radius
of a given blood vessel were deﬁned as ‘perivascular’, and F4/80+ cells present in
areas beyond this region were deﬁned as ‘avascular’. Co-localisation of staining was
quantiﬁed using NIS Elements Software or manual blinded counting using the Cell
Counter plugin on ImageJ where indicated.
Second-harmonic generation imaging. Second-harmonic generation was ana-
lysed in sections of fresh frozen mouse mammary tumours and wounded skin
embedded in OCT using a ZEISS 7MP multi-photon microscope. A 20×/1.0 DIC
VIS-IR M27 75 mm objective immersed with water and a Coherent Chameleon Ti:
Sapphire laser were used at 900 nm with SP 485 and BP 575–610 ﬁlters. Laser
power and detector settings were kept constant throughout multiple sample ima-
ging. Second-harmonic generation signal was quantiﬁed using ImageJ from
representative ﬁelds of view.
Transcriptomic and patient survival data. Breast, lung and gastric cancer patient
survival data were acquired from the Kaplan–Meier plotter76–78. Data have been
selected and extracted using R, with Biobase and Limma libraries. Survival groups
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for hi and low expression of the HWCs were selected based upon ‘best cut off’ for
each data set (data set GSE62254 was excluded from the gastric cancer survival
curves due to its extended parameters). Healing wound mRNA expression data
were obtained from the NCBI’s Gene Expression Omnibus with accession numbers
GSE2300628 and GSE2891437 and from ArrayExpress with accession number E-
MTAB-132336. The microarray data for FAP+ TAMs and M0 macrophages are
accessible through GEO Series accession number GSE113034 [https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE113034].
Statistics. Normality and homogeneity of variance were determined using a
Shapiro–Wilk normality test and an F-test, respectively. Statistical signiﬁcance was
then determined using a two-sided unpaired Student’s t test for parametric or
Mann–Whitney U-test for nonparametric data using GraphPad Prism 6 software.
When comparing paired data, a paired ratio Student's t test was performed. A
Welch’s correction was applied when comparing groups with unequal variances.
For microarray gene analysis, signiﬁcance of differences (fold change) between the
groups were assessed with Partek® Genomics Suite® software (Partek®) using an
ANOVA test. Correction for multiple hypotheses was applied to P values by
controlling the percentage of false discovery rate. Adjusted P values of <0.01 were
considered signiﬁcant. Statistical analysis of tumour growth curves was performed
using the 'CompareGrowthCurves' function of the statmod software package79. No
outliers were excluded from any data presented and all experiments were replicated
at least twice.
Study approval. The use of animals for this study was approved by the Ethical
Review Committee at King’s College London and the Home Ofﬁce, UK. Human breast
adenocarcinoma tissue was obtained with informed consent under ethical approval
from the King’s Health Partners Cancer Biobank (REC reference 12/EE/0493).
Data availability. The mircroarray data that support the ﬁndings of this study are
available through GEO Series accession number GSE113034. The authors declare
that all other data supporting the ﬁndings of this study are available within the
paper and its supplementary information ﬁles.
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